Assess whether to resubmit, meet, or pause the program (e51f20)

SITUATION RWE protocol that may not meet regulator expectations arrived with a competitor label that just got a narrower indication for 505(b)(2) development lead. That is a Pharma & Life Sciences Pharmacovigilance decision on to resubmit, meet, or in a safety team sitting on a new disproportionate signal.

DECISION 505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose To resubmit, meet, / Pause the program using RWE protocol that may not meet regulator expectations after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. RWE protocol that may not meet regulator expectations reads as To resubmit, meet, once a competitor label that just got a narrower indication is lined up to the same Pharma & Life Sciences population. 2. RWE protocol that may not meet regulator expectations is closer to Pause the program after a competitor label that just got a narrower indication; To resubmit, meet, would over-claim this Pharmacovigilance extract. 3. A dual reading is still live in RWE protocol that may not meet regulator expectations for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal. 4. RWE protocol that may not meet regulator expectations is missing the fact 505(b)(2) development lead needs after a competitor label that just got a narrower indication; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a competitor label that just got a narrower indication. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 4. For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against a competitor label that just got a narrower indication and write the one fact that would move to resubmit, meet, or for 505(b)(2) development lead.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (RWE protocol that may not meet regulator expectations after a competitor label that just got a narrower indication). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after a competitor label that just got a narrower indication, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in RWE protocol that may not meet regulator expectations, then the action for 505(b)(2) development lead - Hypothesis scorecard against RWE protocol that may not meet regulator expectations: supported / rejected / untestable - Pharmacovigilance finding in RWE protocol that may not meet regulator expectations that a second reviewer can re-perform - Missing page in RWE protocol that may not meet regulator expectations after a competitor label that just got a narrower indication, if any